Catalyst
Slingshot members are tracking this event:
Seattle Genetics (SGEN) Granted Breakthrough Therapy Status by FDA for Adcetris in Patients with CD30-Expressing Mycosis Fungoides (MF) and Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SGEN |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 10, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Breakthrough Therapy Status, Fda, Adcetris, Cd30-expressing Mycosis Fungoides, Primary Cutaneous, Anaplastic Large Cell Lymphoma, Pcalcl, Mf
